Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 19Active not recruiting 5Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 21Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Radiotherapy 10Doxorubicin 10Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Injections 7Etoposide 7Leucovorin 6Ipilimumab 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Radiosurgery 5Prednisone 5Pemetrexed 5Methotrexate 5Dexamethasone 5Cetuximab 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × ribociclib × 30 days × Clear all
NCT06075758 2026-06-01

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Novartis

Completed
175 enrolled
Breast

Breast Neoplasms

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡